CABALETTA BIO INC Share Price Today: Live Updates & Key Insights

CABALETTA BIO INC share price today is $2.99, up -3.29%. The stock opened at $3.04 against the previous close of $3.04, with an intraday high of $3.24 and low of $2.94.

CABALETTA BIO INC Share Price Chart

CABALETTA BIO INC

us-stock
To Invest in {{usstockname}}
us-stock

CABALETTA BIO INC Share Price Performance

$2.99 -0.0329(-3.29%) CABA at 23 Mar 2026 12:21 PM Biotechnology
Lowest Today 2.94
Highest Today 3.24
Today’s Open 3.04
Prev. Close 3.04
52 Week High 3.78
52 Week Low 0.99
Day’s Range: Low 2.94 High 3.24
52-Week Range: Low 0.99 High 3.78
1 day return -
1 Week return -7.23
1 month return +1.02
3 month return +23.17
6 month return +27.98
1 year return +72.51
3 year return -60.61
5 year return -75.72
10 year return -

CABALETTA BIO INC Institutional Holdings

Bain Capital Life Sciences Investors, LLC 10.05

Jennison Associates LLC 9.25

Adage Capital Partners Gp LLC 9.17

T. Rowe Price Investment Management,Inc. 8.69

T. Rowe Price Small-Cap Value 5.36

Cormorant Asset Management, LLC 5.19

Vanguard Group Inc 4.59

Jennison Health Sciences Equity 3.65

PGIM Jennison Health Sciences Z 3.65

T. Rowe Price U.S. SC Value Eq Tr-D 3.42

Vanguard Total Stock Mkt Idx Inv 2.94

Millennium Management LLC 2.84

Two Sigma Investments LLC 1.91

BlackRock Inc 1.68

SUPERSTRING CAPITAL MANAGEMENT LP 1.60

Renaissance Technologies Corp 1.58

Morgan Stanley - Brokerage Accounts 1.53

T. Rowe Price Associates, Inc. 1.35

Woodline Partners LP 1.30

Schonfeld Strategic Advisors LLC 1.25

Geode Capital Management, LLC 1.13

JPMorgan Chase & Co 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Marshall Wace Asset Management Ltd 1.00

Opaleye Management Inc 0.93

T. Rowe Price Health Sciences 0.89

Schroder Investment Management Group 0.79

iShares Biotechnology ETF 0.66

Fidelity Extended Market Index 0.51

Raiffeisen-Health&Wellbeing-ESG Akt A 0.47

T. Rowe Price US Smlr Coms Eq A 0.35

Northwestern Mutual Ser Small Cap Value 0.33

T. Rowe Price Small-Cap Value Equity 0.33

DFA US Small Cap I 0.30

Blackrock Extended Mkt Fund CF 0.25

iShares Micro-Cap ETF 0.24

T. Rowe Price U.S. Equities Tr 0.24

Extended Equity Market Fund K 0.21

Invesco RAFI US 1500 Small-Mid ETF 0.19

Fidelity Total Market Index 0.18

CABALETTA BIO INC Market Status

Strong Buy: 8

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

CABALETTA BIO INC Fundamentals

Market Cap 283.02 M

PB Ratio 2.1052

PE Ratio 0.0

Enterprise Value 159.46 M

Total Assets 185.05 M

Volume 1738573

CABALETTA BIO INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-1426000 -1.4M, FY22:null 0.0M, FY21:null 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Net worth FY23:-67675000 -67.7M, FY22:-51811000 -51.8M, FY21:-45532000 -45.5M, FY20:-32491000 -32.5M, FY19:-15099000 -15.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-345000 -0.3M, Q2/2025:-468000 -0.5M, Q1/2025:-485000 -0.5M, Q3/2024:null 0.0M, Q2/2024:-426000 -0.4M

Quarterly Net worth Q3/2025:-44866000 -44.9M, Q2/2025:-45128000 -45.1M, Q1/2025:-35943000 -35.9M, Q3/2024:-30629000 -30.6M, Q2/2024:-27602000 -27.6M

About CABALETTA BIO INC & investment objective

Company Information Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Organisation Biotechnology

Employees 148

Industry Biotechnology

CEO Dr. Steven A. Nichtberger M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

CABALETTA BIO INC FAQs

What is the share price of CABALETTA BIO INC today?

The current share price of CABALETTA BIO INC is $2.99.

Can I buy CABALETTA BIO INC shares in India?

Yes, Indian investors can buy CABALETTA BIO INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy CABALETTA BIO INC shares in India?

You can easily invest in CABALETTA BIO INC shares from India by:

Can I buy fractional shares of CABALETTA BIO INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of CABALETTA BIO INC?

CABALETTA BIO INC has a market cap of $283.02 M.

In which sector does CABALETTA BIO INC belong?

CABALETTA BIO INC operates in the Biotechnology sector.

What documents are required to invest in CABALETTA BIO INC stocks?

To invest, you typically need:

What is the PE and PB ratio of CABALETTA BIO INC?

The PE ratio of CABALETTA BIO INC is N/A and the PB ratio is 2.11.